Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NIfuWJhHfW6ldHnvckBCe3OjeR?= MXKwMlfPxE1? NGOyUnUzPGh? NFT4empmfGijbn;s NI\jb41mdmijbnPld{BGVmGFIHHj[ZR6dGG2aX;uJIFv\CCrbnPy[YF{\XNiRV7hR{Bi[nWwZHHuZ4UhcW5idHjlJJRwfGGuIHPlcIwhdHm|YYTlJIFv\CCjdDD0bIUh[2WubDDzeZJn[WOn MXSyOVc5PzB5OR?=
TE13 NHX0VGxHfW6ldHnvckBCe3OjeR?= M3XVXVAvO87:TR?= Ml;VNlRp MnzKeZAuemWpdXzheIV{KFKDU2PGOWEhdGW4ZXy= MUeyOVU4QTZ4NR?=
TE13 MVzBdI9xfG:|aYOgRZN{[Xl? NIG2[mYxNjQQvF2= MYCyOIg> NFX1dGtqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w M1\OWVI2PTd7Nk[1
MEFs M4\6PGZ2dmO2aX;uJGF{e2G7 MlfzOe69VQ>? MnS4NVZp NX\LSFZUcW6lcnXhd4V{KHSqZTDFVGVEKGG2dHHjbI1mdnRuIGTpdkBl\WyrdnXyfUBidmRidHjlJIVn\mmlaXXuZ5khd2ZicHXk[ZN1[WxiZn;ycYF1cW:w MV:yOVQ5OjZ|NB?=
SW480  NWO4fJBwTnWwY4Tpc44hSXO|YYm= NIrxfGUxNjIQvF2= NH;DcIc1QGh? NWnnSpptTE2VTx?= MX\y[ZZmenOnczDFUXQ> M1y1R|I2PDN2OUm3
PC3  NXjENYRTTnWwY4Tpc44hSXO|YYm= MnHMNE4y|ryP NE[1T4g1QGh? NUHHN2lTTE2VTx?= MV3y[ZZmenOnczDFUXQ> MlfyNlU1OzR7OUe=
SW480  M3TUUWZ2dmO2aX;uJGF{e2G7 M1fsVlAvOc7:TR?= Mlz2OFhp MmPnSG1UVw>? MmXBZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w M3vBe|I2PDN2OUm3
PC3  MnPESpVv[3Srb36gRZN{[Xl? NVfHSG9FOC5zzszN NIftPGE1QGh? M3PxTmROW09? NITXVlNifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= MmO1NlU1OzR7OUe=
SW480  M17sZmZ2dmO2aX;uJGF{e2G7 M3LBfVAvOc7:TR?= MXW0PIg> MUXEUXNQ MmfJbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? NYXJTXd4OjV2M{S5PVc>
PC3  NEHPOGhHfW6ldHnvckBCe3OjeR?= NVPTeZk5OC5zzszN MVu0PIg> NVmzPHBWTE2VTx?= M3;OSolv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? MlrBNlU1OzR7OUe=
A431 MkXmRZBweHSxc3nzJGF{e2G7 Mon6Nk8yOC93MD:xNFBvVQ>? MmnqOFhp MlPQSG1UVw>? MnvLbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3Sq NGPmR2szPTN5MUC2PS=>
A431 MlHhSpVv[3Srb36gRZN{[Xl? NX7JOms1PTCwTR?= MUmyM|YwOTJxMkTo NGHCeGJFVVOR MWHhZ5RqfmG2ZYOgdFIyKGGwZDDpcohq[mm2czDBWGY{KGW6cILld5Nqd25? MUiyOVM4OTB4OR?=
MDA-MB-231 M{jvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvMeGExNTZyMH7N M1LINlI1cA>? MVvEUXNQ M2HscGlEPTBib3[gNVAxdk1? NFyyOFYzPTF7MkeyNS=>
MCF7 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfXfVZjOC14MEDuUS=> M3fHc|I1cA>? NX;Pb2hjTE2VTx?= MXrJR|UxKG:oIEe1cm0> M2HJPVI2OTl{N{Kx
SKOV-3 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTydFgyNTFyzszN NYrYZWpCOjSq MVrEUXNQ MWrJR|UxKG:oIEWuOu69VQ>? MXuyOVE3QTR7MR?=
A549 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrINU0yOM7:TR?= MlewNlRp NIWzSYNFVVOR NIPKXWlKSzVyIH;mJFMvOs7:TR?= MXeyOVE3QTR7MR?=
SKOV-3 MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWewMlEuOc7:TR?= NY\ET3RFPDiq MkjPSG1UVw>? M1\heWlEPTBib3[gNE44|ryP NFjYSFUzPTF4OUS5NS=>
A549 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjQSFZzOC5zLUJOwG0> NYL5UHhnPDiq MUPEUXNQ M2r3dWlEPTBib3[gNE4zQM7:TR?= NGjCfmozPTF4OUS5NS=>
SKOV-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[0fIdmOC5yMT2wMlnPxE1? MVO3Nog> MX3EUXNQ M2fRfGlEPTBib3[gNE4{Os7:TR?= M4\nV|I2OTZ7NEmx
A549 NUnGWZF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7tTJUxNjBzLUCuPe69VQ>? Mo[3O|Jp MUHEUXNQ NXu1TYxUUUN3MDDv[kAxNjB4zszN MnjZNlUyPjl2OUG=
HeLa NWThXFNtTnWwY4Tpc44hSXO|YYm= M3HhXVI2OG6P MknENVZp MoP2SG1UVw>? NYrIU3l3cW6lcnXhd4V{KEO\UEHBNUBuWk6DIHX4dJJme3Orb39CpC=> MlX0NlUyOTZ4OEi=
CNE2 NUPWcHVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuzUpdlOTByLU[wNI5O NUm0[nJOOjRxNEivO|Jp M3TiUIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NX3wXmVlOjR7Nkm5NFE>
PC3 MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[xNFAuOTByMH7N NUjnNXA6OjSq NXLBVXp6UUN3MDDv[kA{ODCwTR?= NIH5VHczPDh3NE[1PC=>
LNCaP NGDqSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6xNFAuOTByMH7N NILCfYEzPGh? MlfPTWM2OCCxZjCzNFBvVQ>? NXi3dm55OjR6NUS2OVg>
HeLa  M2f2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfZcXoz|ryP MYG0PIg> M1;3ZYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhZo92fCB{NTW= MWOyOFg1PjF|NR?=
HMEC-1  M3y4UWZ2dmO2aX;uJGF{e2G7 MoLDN|Axdk1? NV3jcmJPOjSq NGfCeGtqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZtMgWmVITlJ|wrDtVm5C NXXNO4VwOjR5MUC2N|E>
HeLa MonxSpVv[3Srb36gRZN{[Xl? NFXRc2cydU1? NYqxPGV4OC53aB?= MVvhZo9tcXOqZYOgeIhmKHSxdHHsJGhFSUNiYXP0bZZqfHl? MUCyOFcxPzR5NB?=
ACP02 MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGyOVAwOzVyL{WwNI5O MVuyOIg> MX7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O MXeyOFY3QDV2Nx?=
ACP03 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDU[G9sOjVyL{O1NE82ODCwTR?= M4DTc|I1cA>? MkHF[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? MYiyOFY3QDV2Nx?=
U87 GBM NUfVPVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzKXFIyODBxM{CwM|UxOCCwTR?= MXG3NkBp M2\w[|ExOCViZYToZY5wdA>? NWPwSG8{emWmdXPld{Bu\WGwIHPlcIwhdnWvYnXyJIJ6KDNzLDC1OEwh[W6mIEW4xsAm NGrRfFczPDR4NEi0NS=>
U87 GBM NYHDU|lmTnWwY4Tpc44hSXO|YYm= NVf4UmhiOTByL{WwNEBPdQ>? MXO0PEBp M2L1NFExOCViZYToZY5wdA>? MXfJcoR2[2W|IGPlcoV{[2WwY3WtUIls\SCDbITldoF1cW:wczDpckBPfWOuZXHyJG1wenCqb3zv[5k> NF:yOJIzPDR4NEi0NS=>
RPE NVqzSndzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XNTFAvOi9yLkSvNE45NzFizszN NGTXZVMzPC92OD:3NkBp NXHVWZVtTE2VTx?= NFT2PGtqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBjgSClZXzsJIN6[2ynIHHydoV{fA>? MmH1NlQ1PTZ4MEK=
HT29  NU\ncVRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofJNVgxKG6P M3O0[|czKGh? MW\JR|UxKG:oIEG4NEBvVQ>? MXWyOFM3QDJ4NR?=
hMSCs MYLGeY5kfGmxbjDBd5NigQ>? MnXvOk4zPSCwTR?= MXWyOEBp NG\RR3RFVVOR NInVUHN{fGGkaXzpfoV{KEirc4TvcoUhSWOndInsZZRqd25iYX7kJJRp\SCHeIDy[ZN{cW:wIH;mJHBtfXKrcH;0[Y51KEenbnXz NGn4PZozPDNzMkO1Oi=>
Huh7  MnrRSpVv[3Srb36gRZN{[Xl? NWL1bHFqOC5zL{CuOU8yNjBizszN Mn[1NlRp MYjzeZBxemW|c3XzJHlVUESFMjDn[Y5mKGW6cILld5Nqd25? MWeyOFI3QTZ5Mh?=
SKOV3 NWLDZldrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;3VZYxNjB3LUKg{txO NYfuUFV[OTBxMkSvOFghcA>? MlrKSG1UVw>? MV\t[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NHP2VY0zPDJ{M{iwNS=>
A2780 M17OdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzPNE4xPS1{IN88US=> MY[xNE8zPC92ODDo NGfVc3VFVVOR NUHR[m44dWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NFG5[ZUzPDJ{M{iwNS=>
SRA01/04  MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq1WmFZOC5{IN88US=> MnfzOFghcA>? M13abWROW09? Mk\Kd5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> MmHmNlQyPTd6N{i=
HLEB3 NYTwfIE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq0[2VuOC5{IN88US=> Mk\FOFghcA>? NIXRbnhFVVOR NI\2WnF{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? NFjOUVgzPDF3N{i3PC=>
SRA01/04  MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqwMlQwOC56IN88US=> MXW0PEBp NGTRb3VFVVOR MoG3bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NWD4WWh2OjRzNUe4O|g>
HLEB3 M4XCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC4NE41NzBwODFOwG0> NYDic3RDPDhiaB?= M{C5fWROW09? NV7TeWpocW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3GzXFI1OTV5OEe4
HCT116 NFPlV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7PNE4zKM7:TR?= MmWyNVIhcA>? MWPlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IILh[IlifGmxbh?= NF7pfo4zPDF{MkKzNS=>
CA46 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Hr[lMwPi9zMj:yOE81QCCwTR?= MXS0PEBp NVrXPYcxcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDheEAzPCCjbnSgOFghdk4EoB?= NETDelYzPDB4NEm1NS=>
PMNs Ml\pSpVv[3Srb36gRZN{[Xl? NGTzc5Q{OCCwTR?= MoixOFghcA>? NWf4PFFEcW6qaXLpeJMh\W[oZYLvZ5l1d3OrczygTGRCSyCjY4Tpeol1gSCjbnSgVoFkKGGldHn2bZR6 M37xOVI{QTh6NkG3
H1299 NHLwZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDTVmgyyqEQvF5CpC=> NXnUblg5OjRxNEivO|IhcA>? NUDORVlr\XSqYX7vcC=> NXXLWnpOcW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq MVyyN|kyPjZyOR?=
A549 NGXXT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjaNE4zPS9yLkWvNUDPxE1? NVTSSoRUOjRxNEivO|IhcA>? NYDkVIdi\XSqYX7vcC=> NV;GWItHcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MnLMNlM5Pjd7OUG=
H1299 NE\KeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PETFAvOjVxMD61M|Eh|ryP NE\xN44zPC92OD:3NkBp MYrleIhidm:u M2jFPIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NYfK[GRpOjN6Nke5PVE>
A549 NFG0dYZCeG:ydH;zbZMhSXO|YYm= MoD3NE42NzFizszN NUf4PWxYPDhiaB?= MXHleIhidm:u NF3R[XdqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MUmyN|g3Pzl7MR?=
H1299 M1e3OWFxd3C2b4Ppd{BCe3OjeR?= MXKwMlUwOSEQvF2= MXy0PEBp MYPleIhidm:u M3iwU4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXeyN|g3Pzl7MR?=
SUM149PT MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXONk84NjVxMUCg{txO M13GN|Q5KGh? NXLOUVdzTE2VTx?= NVvwWoFicW6mdXPld{Bk\WyuIHTlZZRpKGG2IEKg{txOKGmwc3Xud4l1cX[nbIm= NGfNUnkzOzd7Mk[zPC=>
SUM190PT MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;4d3Y2OC9zMECvNlUxKG6P MVW0PEBp NWrIVFhvTE2VTx?= MoPDbY5lfWOnczDj[YxtKGSnYYToJIF1KDVyIH7NJJNmdnOrdHn2[Yx6 M4fwS|I{Pzl{NkO4
HCT1 NFHIUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPRNE4zNzFwMD:1MlAh|ryP MU[xNk8zPC9|Nj:0PEBp M1LV[4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NHTKV|gzOzd5MECwNC=>
Lovo MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW3NE4zNzFwMD:1MlAh|ryP M1nNU|EzNzJ2L{O2M|Q5KGh? NHu0fWVqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M3rJRVI{PzdyMECw
AGS MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j5e|AvODF3LUGg{txO NEXMZ3g4OiCq MV\pcoR2[2W|IHPlcIwh\GWjdHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?= MnjhNlM4PDVyMkS=
Huh7 M1;hU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETCUJQyKM7:TR?= MnLhNlQhcA>? NYPWOmVKTE2VTx?= M{HxWpJm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh NIHo[VczOzZ2M{mzNy=>
ECC1 MXLGeY5kfGmxbjDBd5NigQ>? NXPrbGhxPTByIH7N MnnYOUBl MYHEUXNQ M4S3[olv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NF3xZogzOzV|MEe2PS=>
HEC1A MoD5SpVv[3Srb36gRZN{[Xl? MWC1NFAhdk1? MUi1JIQ> NUewNIhtTE2VTx?= MXvpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NEDmU24zOzV|MEe2PS=>
EN1 MUjGeY5kfGmxbjDBd5NigQ>? M2\qVlUxOCCwTR?= NGHy[oc2KGR? NF3kXXBFVVOR NYrXbWdQcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= M2TrUVI{PTNyN{[5
MFE296 NFe2VFBHfW6ldHnvckBCe3OjeR?= M3e1c|UxOCCwTR?= NWXjU4ZUPSCm NYHpWIl{TE2VTx?= MWLpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MkH6NlM2OzB5Nkm=
HASMCs NYXaSY5KTnWwY4Tpc44hSXO|YYm= MnnXNE02ODBibl2= M1fJO|Yh\A>? MYrkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> MXSyN|UyQDR4Nx?=
U373 NGXiS29HfW6ldHnvckBCe3OjeR?= NWeyVVF2OC5{NT:wMlUwOSEQvF2= NVTrRWdFOjRiaB?= Mk\qbY5kemWjc3XzJHBTNUJiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1RZpi\EN? MWeyN|Q4PDF5MR?=
ARN8  NYf1TXh2TnWwY4Tpc44hSXO|YYm= NXHQWZFCOC5yNT2yJO69VQ>? M3mwT|I1KGh? NFrNeoJz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? M2Dod|I{PDdyNUSw
MCF7 M2n5fmZ2dmO2aX;uJGF{e2G7 NGP4c2sxNjB3LUKg{txO M2XjeFI1KGh? M3n1TZJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDwOVMu\GWyZX7k[Y51KGenbnXzJIJ6KE63dHzpck0{ MW[yN|Q4ODV2MB?=
H1299  MoLkSpVv[3Srb36gRZN{[Xl? MVmwMlM{6oDVMdMgxtVO MX2yOE81QCCq M4jpPWROW09? NU\l[lNRcW6lcnXhd4V{KEVvY3HkbIVzcW5icILveIVqdiCuZY\lcJMh\G:|ZTDk[ZBmdmSnboTsfS=> MWGyN|Q3OTl5NR?=
H1299 NEGwNGxHfW6ldHnvckBCe3OjeR?= NV:3UWFbOC53IN88US=> MYi0PEBp M3fBU2ROW09? NHTkOHZqdmirYnn0d{B1cGVibXnndoF1d3K7IIDveIVvfGmjbDDjc41jcW6nIIfpeIghe2muaXLpcolv MkP3NlM1PjF7N{W=
H1299 M3vwcmZ2dmO2aX;uJGF{e2G7 M{L4[VAvPSEQvF2= M33qR|Q5KGh? M2\LVWROW09? NW\6dmw{cW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6= M1zndlI{PDZzOUe1
MG-63  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTEU4gxNjNizszN NYHiWYp1OTJvOU[gbC=> MUnEUXNQ MmfhbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= NUTVd5NXOjN2NUG4NVc>
LM8 NHrqbHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;j[lAvOyEQvF2= M33jUlEzNTl4IHi= MkL1SG1UVw>? NHzIcY9qdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu MoDQNlM1PTF6MUe=
K562 NUPVTYNETnWwY4Tpc44hSXO|YYm= MonsNE42KM7:TR?= MlfWNlQhcA>? NWjPSVRv\XSqYX7vcC=> M3jrZYRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv NFqyUVUzOzR|MEm1Oy=>
HEL NYX3d5pJTnWwY4Tpc44hSXO|YYm= MlXtNE42KM7:TR?= M2jIVlI1KGh? NH3mW3FmfGijbn;s MWHk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> NWD3VFhjOjN2M{C5OVc>
HL60 NXeyZnM{SXCxcITvd4l{KEG|c3H5 M2LRRVEh|ryP NFXlT5IzPCCq M4XzNYlv\HWlZYRCpINmdGxiZHXheIg> MVyyN|QxODVzOR?=
KG1 NVO0PGFWSXCxcITvd4l{KEG|c3H5 M3zDfVEh|ryP NWj4e25xOjRiaB?= NUPtXoVHcW6mdXPld:Kh[2WubDDk[YF1cA>? NULU[3FrOjN2MEC1NVk>
Kazumi NUDzRWszSXCxcITvd4l{KEG|c3H5 NIrFR4oyKM7:TR?= NXnpNppiOjRiaB?= MX;pcoR2[2W|wrDj[YxtKGSnYYTo Mn7qNlM1ODB3MUm=
K562 Mo\MRZBweHSxc3nzJGF{e2G7 Mny3NUDPxE1? MUKyOEBp NFHmd|FqdmS3Y3XzxsBk\WyuIHTlZZRp NGLBUZkzOzRyMEWxPS=>
THP1 MYfBdI9xfG:|aYOgRZN{[Xl? MlTlNUDPxE1? MVqyOEBp NXnv[pNXcW6mdXPld:Kh[2WubDDk[YF1cA>? NYX1b3FyOjN2MEC1NVk>
SH-SY5Y MlrxSpVv[3Srb36gRZN{[Xl? MWGyOVAhdk1? NFe2cZcyPiCq M4nDRYNp[W6pZYOg[ZhxemW|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi= MkXHNlM{OjZ2MkK=
HEK293 MUPGeY5kfGmxbjDBd5NigQ>? MUWxJOK2VcLi MXuxPEBpyqB? NHrvXmlqdmirYnn0d{B1cGVia3HsbZJqdi15LX3l[IlifGWmIILlZ5J2cXSvZX70JI9nKHO7boDobYxqdi1zIHHn[5Jm\2G2ZYOgbY51dyCjZ3fy[ZNwdWW| M1Tae|I{Ojh2OES4
HTK NUD4WGo5TnWwY4Tpc44hSXO|YYm= MoXaOFAxKG6P MUW3NkBp Mm\HbY5pcWKrdIOgWGdHNc7{4pETTY5lfWOnZDDNfY9ncWK{b3LsZZN1KESrZn\ldoVvfGmjdHnvci=> NH;oNWwzOzJ6NECwNi=>
HTK NGfTTWhHfW6ldHnvckBCe3OjeR?= M3zZWlExOC16MEDuUS=> MXq3NkBp M1\CWoJtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w MXSyN|I5PDByMh?=
Caco-2  M3nXdGZ2dmO2aX;uJGF{e2G7 NEPaPXUyKML3TdMg MVmyOEBp NYLic21n\GWlcnXhd4V{KFOHUmSgdJJwfGWrbjDlfJBz\XO|aX;u MWWyN|E6PTB5MB?=
HeLa NE\tV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLwNVAxKG6P NGPsTW4zPCCq NFrJe2NFVVOR NULFNFB3UUN3MDDv[kAyODCwTR?= MV[yN|E3PTd2OB?=
HeLa NV61U4s4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[5OFAhdk1? NVjMfpBSPDhiaB?= NXvl[2I{TE2VTx?= Mnz2TWM2OCCxZjC0NI5O NGPmcZYzOzF4NUe0PC=>
HeLa M2m5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTHNlAhdk1? Mn7nO|IhcA>? MXzEUXNQ Mk\FTWM2OCCxZjCyNI5O MVSyN|E3PTd2OB?=
HeLa M3TvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTKc4lTOTBxM{CvOVAhdk1? MXS3NkBp M1rQVGROW09? NITVV3BqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDNUXAhMM7WzrjtLUBtd3O|IHPlcIx{KGSxc3Wg[IVx\W6mZX70cJk> NUDEVVE1OjNzNkW3OFg>
MDA-MB-231 M{WzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTweI1COjVvNECwJI5O M2TyelQ5KGh? MnGwTWM2OCCxZjCyOlMvOm6PwrC= M4PmZVI{ODV3MUm4
MCF-7  M3rNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHEV2gzPS12MECgcm0> MWC0PEBp Mk\1TWM2OCCxZjCyNlAvPG6P NIjXdI4zOzB3NUG5PC=>
ECC-1  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrGRmgyODBibl2= NVHDWWZ[OjRiaB?= M1XheoV1cGGwb3y= NX\UTZVzcW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{Wl Mle5NlMxOjh6MEO=
HEC-1A M{PXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnroNVAxKG6P NXqyUoE{OjRiaB?= NVHxfVJb\XSqYX7vcC=> NYW3W3lZcW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{ml NV3a[phUOjNyMki4NFM>
NHAC-kn NFrteXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnH[FZ7OTBxMUCwM|UxOCCwTR?= Mo\yNVIhcA>? NGSwbYNFVVOR MXvJR|UxKG:oIEWwNI5O MXGyN|AyPzh5MR?=
A549 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[yOVAhdk1? NWLwTmtYPi15MjDo NY\VRW9YTE2VTx?= M1zPXYNifXOnczDhJIdz\WG2ZYKgbY5pcWKrdH;yfUBm\m[nY4SgZ49u[mmwZTD3bZRpKFS[VDDvdkBmemyxdHnubYI> NVnJRmtwOjJ7OUS3PFA>
MG-63 NYXiS4s3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2zNFAhdk1? M2\TdFEzKGh? Ml7KSG1UVw>? M4CwcolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A5PiV? NYPSZpY2OjJ5OUmzN|g>
MG-63 M3HpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXvVG9mOzByIH7N NUPnb2ZPOjRiaB?= NIjYW3JFVVOR M3;TdIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A3PyV? NEG2bIczOjd7OUOzPC=>
MG-63 M1\EWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe0XHp2OzByIH7N NXLmOIxwPDhiaB?= NHizfZpFVVOR MUXpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOVYm NUTz[I9WOjJ5OUmzN|g>
HL60  NGDlW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHkfJVZOTVyLUO1NEBvVQ>? M4rWSVI1KGh? NUf4cnI{cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? NEjxcJgzOjd3M{ezPS=>
U937 M3zHRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSybmd7OTVyLUO1NEBvVQ>? NYfrRWNzOjRiaB?= MUHpcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N NVK4VZRNOjJ5NUO3N|k>
SCC-6 MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X6ZlIxOC1|MkCwJI5O NWrNRmUzOTJxMkSvOFghcA>? MUTEUXNQ MV\pcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NIO3e2IzOjV3MkOyNS=>
U87  M2m5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLtUVgyODBvM{CwJI5o NETRO3gzPCCq NE[3ZmlqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= MYSyNlI4ODh2OR?=
K562 M1jyOmZ2dmO2aX;uJGF{e2G7 NH;3eJAyKM7:TR?= MoPjNVIhcA>? NXj0eI81TE2VTx?= Mof1[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= M3z5SlIzOTd7MUm4
Reh NH2xRlNHfW6ldHnvckBCe3OjeR?= MnTvNE4{NzFizszN Mon6NVIhcA>? MWjEUXNQ NW\JZmhR\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> M4fqe|IzOTd7MUm4

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03735173 Not yet recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable
NCT02959905 Unknown status Metastatic Melanoma BGI China|Sun Yat-sen University December 2016 Phase 1
NCT03133819 Enrolling by invitation Diabetes; Neuropathy Polyneuropathy (Manifestation) Chang Gung Memorial Hospital November 2016 Not Applicable
NCT02486965 Recruiting Fibromyalgia University Hospital Brest October 2015 Not Applicable
NCT01954433 Active not recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG) Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Completed Pain Massachusetts General Hospital June 2012 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID